CDC Report Addresses Impact of COVID-19 on Antimicrobial Resistance
Increases in resistant infections from 2019 to 2020 were seen for carbapenem-resistant Acinetobacter and antifungal-resistant Candida auris.
Increases in resistant infections from 2019 to 2020 were seen for carbapenem-resistant Acinetobacter and antifungal-resistant Candida auris.
The effectiveness of maternal vaccination against COVID-19 hospitalization in infants was 80% during delta and 38% during omicron.
A 50mcg booster dose of mRNA-1273.214 elicited significantly higher neutralizing antibody responses against omicron subvariants BA.4 and BA.5 in adults.
The Novavax COVID-19 vaccine is administered intramuscularly as a 2-dose primary series (0.5mL each), separated by 3 weeks.
Less than half of patients seroconverted after 2 doses of a COVID-19 vaccine, but 56% of those patients seroconverted after a third dose.
A subset of patients with non-small cell lung cancer have “very suboptimal” responses to COVID-19 vaccination, according to researchers.
Vaccination is estimated to have prevented 58% of expected deaths in adults from Sept. 1-30, 2021.
Patients with lung cancer who underwent COVID-19 vaccination while receiving immune checkpoint inhibitors did not have an increased risk of immune-related adverse events.
More deaths would have been averted had vaccine coverage targets from COVAX and WHO been met, according to researchers.
Two treatment-related factors and the frequency of 6 cell types were associated with response to COVID-19 vaccination.